10 employees
Medisyn Technologies develops pre-qualified proprietary drug compounds for breast, renal, prostate, and lung cancer treatments.
1999
$1.5M
from 1 investors over 1 rounds
Medisyn Technologies raised $1.5M on February 17, 2005
Investors: Sherpa Partners